Increased resources are required in patients with low cyclosporine bioavailability.
Schroeder
T J
TJ
Departments of Pathology and Laboratory Medicine, University of Cincinnati Medical Center, OH 45267-0714, USA.
Shah
M
M
Hariharan
S
S
First
M R
MR
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001741:Black or African American; D000368:Aged; D001682:Biological Availability; D002908:Chronic Disease; D016572:Cyclosporine / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010359:Patient Readmission / Q000706:statistics & numerical data; D044469:Racial Groups; D012189:Retrospective Studies; D013997:Time Factors; D044465:White People
D007166:Immunosuppressive Agents; D016572:Cyclosporine